TL;DR
This study reveals that the broadly neutralizing antibody VRC01, used in HIV prevention trials, can select for rare escape mutations in the virus shortly after infection. These mutations can reduce the effectiveness of VRC01 and related antibodies, highlighting the need for next-generation antibodies with broader coverage and higher potency for durable HIV prevention.
What Problem Does This Paper Address?
Broadly neutralizing antibodies (bnAbs) are a promising strategy for preventing HIV infection. However, a major challenge is the virus's ability to evolve and develop resistance to these antibodies. The Antibody Mediated Prevention (AMP) trials investigated the efficacy of VRC01, a bnAb targeting the CD4 binding site (CD4bs) of the HIV envelope protein, in preventing HIV acquisition. While VRC01 was effective against sensitive HIV strains, its impact on viral evolution after infection, particularly the emergence of resistance, was not fully understood. This paper addresses the critical question of whether VRC01, when administered prophylactically, can drive the selection of de novo (newly arising) escape mutations in individuals who become infected, and if so, how these mutations affect susceptibility to other CD4bs bnAbs.
Methods
The researchers analyzed over 12,000 HIV env gene sequences from 47 participants in the AMP trials. They employed deep sequencing to identify viral variants. To pinpoint escape mutations, they compared sequences from VRC01-treated participants to those from placebo recipients. They also used neutralization assays with pseudoviruses (viruses engineered to display specific HIV envelope proteins) to assess the impact of identified mutations on VRC01 sensitivity and the sensitivity to other CD4bs bnAbs. Structural modeling was used to visualize the location of these mutations within the VRC01 epitope.
Datasets
The study utilized HIV env gene sequences from participants in the Antibody Mediated Prevention (AMP) trials (HVTN 703/HPTN 081 and HVTN 704/HPTN 085). They also used a global database of HIV-1 sequences (from Los Alamos HIV sequence database) to assess the frequency of identified escape mutations in circulating viruses.
Key Insights and Ideas
- VRC01 isn't a perfect shield: While VRC01 is effective, it's not impenetrable. The study shows it can actively select for viral escape mutations shortly after infection.
- Escape mutations are rare but potent: The identified escape mutations are uncommon in the general HIV population, suggesting they might impose a fitness cost on the virus. However, even at low frequencies, they can significantly reduce VRC01's effectiveness.
- Cross-resistance is a concern: Mutations conferring resistance to VRC01 can also reduce sensitivity to other CD4bs bnAbs, complicating treatment and prevention strategies that rely on this class of antibodies.
- Potency matters: More potent bnAbs, like N6 and 1-18, showed greater resilience to these VRC01-selected escape mutations, highlighting the importance of antibody potency in overcoming viral evolution.
- Timing is crucial: The emergence of escape mutations was observed in individuals diagnosed with HIV relatively soon after their last VRC01 infusion, suggesting that maintaining sufficient antibody levels is key.
Key Results
- VRC01-mediated de novo escape mutations were identified in 8 out of 26 VRC01-treated participants, but in none of the 21 placebo participants.
- These escape mutations were found at very low frequencies (<1%) in global HIV sequences.
- The escape mutations were primarily located in the Loop-D and β23/V5 regions of the HIV Env protein.
- These mutations conferred cross-resistance to several CD4bs bnAbs, but more potent bnAbs like N6 and 1-18 largely retained their activity.
- In some cases, double mutations were observed to confer even greater cross-resistance than single mutations.
Limitations and Future Work
- Transient pressure: The authors note that VRC01 pressure is transient, which might limit the opportunity for compensatory mutations to arise and fully restore viral fitness.
- Incomplete neutralization: The study raises concerns about whether resistant variants will persist and potentially undermine future antibody-based interventions, especially if they can be transmitted.
- Distal sites and multiple lineages: The study did not assess escape mutations at distal sites outside the VRC01 epitope, nor did it investigate multiple lineage infections where recombination could facilitate escape.
- Future directions: The findings underscore the need for next-generation bnAbs with improved breadth and potency to enhance the durability and efficacy of antibody-based HIV prevention. Future work should focus on understanding the long-term impact of these escape mutations on viral fitness and transmission, and on developing combination antibody strategies that target multiple epitopes to overcome resistance.
Summary updated